FDA Calls New Breast Cancer Drug A 'Breakthrough'
Newly approved breast cancer drug Ibrance performed well in clinical trials. It kept tumors away twice as long as current treatments.By Madison Burke | February 5, 2015
The U.S. Food and Drug Administration is calling a newly approved breast cancer drug a "breakthrough."
That drug is called Ibrance and treats advanced-stage breast cancer.
The drug is manufactured by Pfizer and targets proteins involved in cancer cell growth. It's intended for postmenopausal women.